Key result
Candesartan cilexetil suppresses aortic aneurysm progression in Marfan mice driven by its inverse agonist activity.
Why the study?
The impact of ARB inverse agonism on Marfan syndrome aortopathy remains poorly understood despite its potential cardiovascular benefits.
Does candesartan cilexetil (with inverse agonist activity) prevent aortic aneurysm formation better than candesartan-7H (neutral antagonist) in Marfan syndrome mice?
Does candesartan cilexetil (with inverse agonist activity) prevent aortic aneurysm formation better than candesartan-7H (neutral antagonist) in Marfan syndrome mice?
Inverse agonist activity of ARBs appears crucial for preventing aortic aneurysm formation in Marfan syndrome, independent of blood pressure lowering.
Answers are grounded in this paper and cite their sources.
Should not yet alter ARB selection in Marfan patients; leaves open translation of inverse agonist benefit to humans.
Background Marfan syndrome (MFS), an inherited disorder caused by FBN1 gene mutations, causes fatal aortic aneurysm. Selective angiotensin II (Ang II) type 1 (AT 1 ) receptor blockade is a preventive option for patients with MFS aortopathy, and recent clinical studies demonstrated that the inhibitory effect of an AT 1 receptor blocker (ARB) losartan on aortic aneurysm growth is equivalent to that of β-blockers. At present, several ARBs are clinically available, and they have drug-specific differences in pharmacological properties. Especially, inverse agonism of ARBs has potential benefits for cardiovascular protection, but its impact on MFS aortopathy remains poorly understood. Methods Candesartan-7H is a candesartan derivative which lacks the carboxyl group critical for inverse agonist activity and works as a neutral antagonist for AT 1 receptor. Candesartan cilexetil (1 mg/kg/day), candesartan-7H (1 mg/kg/day or 20 mg/kg/day), or vehicle was administered to Fbn1 C1041G/+ mice, and aortic aneurysm formation was analyzed using echocardiography, histological staining, and in situ MMP assay. Activation of TGF-β signaling and mechanosensitive signaling was studied using western blot and immunohistochemical analysis. Results Candesartan cilexetil (1 mg/kg/day) and candesartan-7H (20 mg/kg/day) lowered blood pressures equally in Fbn1 C1041G/+ mice, but that candesartan-7H (1 mg/kg/day) did not. Aortic aneurysmal progression in association with aortic wall thickening, degeneration of elastic fibers, deposition of collagen, MMP activation, and TGF-β signaling activation in Fbn1 C1041G/+ mice was significantly suppressed by treatment with candesartan cilexetil (1 mg/kg/day), but not by candesartan-7H even at 20 mg/kg/day. In addition, candesartan cilexetil, but not candesartan-7H, inhibited up-regulation of mechanical stress–responsive transcriptional factor Egr-1 in ascending aorta of Fbn1 C1041G/+ mice. Conclusions Our findings support a crucial role of inverse agonist activity of ARB for prevention of mechanical stress-induced AT 1 receptor activation and aortic aneurysm formation in MFS mice.
No takes yet. Share an insight, caveat, or question.
Yagi et al. (2022) studied Marfan syndrome aortopathy. Candesartan cilexetil vs. Candesartan-7H (1 mg/kg/day or 20 mg/kg/day) or vehicle was evaluated on Aortic aneurysm formation and progression. Candesartan cilexetil, an ARB with inverse agonist activity, significantly suppressed aortic aneurysmal progression in Marfan syndrome mice, whereas the neutral antagonist candesartan-7H did not.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: